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compared with the CsA group, and a further decrease was ob-Cyclosporine withdrawal and mycophenolate mofetil treatment
served with MMF treatment after CsA was withdrawn.effects on the progression of chronic cyclosporine nephrotox-
Conclusion. The combined treatment of CsA and MMF doesicity.
not prevent the development of chronic CsA nephrotoxicity, butBackground. Recent clinical trials of mycophenolate mofetil
MMF treatment after CsA withdrawal does improve chronic(MMF) in chronic allograft nephropathy (CAN) demonstrated
CsA nephrotoxicity. This finding provides a rationale for MMFthat the dose of cyclosporine A (CsA) is one of the critical fac-
treatment in chronic CsA nephrotoxicity.tors in determining graft function in CAN, but the effect of
MMF on chronic CsA nephropathy is undetermined. We un-
dertook this study to evaluate the effect of MMF on CsA-
induced nephrotoxicity in an animal model of chronic CsA
Most immunosuppressive drug regimens depend on thenephropathy.
cyclosporine (CsA) or FK506, even though nephrotoxic-Methods. In the first experiment, Sprague-Dawley rats on
ity is the major dose-limiting adverse effect for both drugsa low-salt diet were treated with CsA (7.5 mg/kg per day) for
10 weeks, or were treated with CsA for five weeks and then [1, 2]. Long-term administration of CsA causes progres-
MMF (20 mg/kg per day) was administered five weeks later. sive renal failure and irreversible renal striped interstitial
In the second experiment, rats were treated with CsA for five fibrosis, tubular atrophy, and hyalinosis of the afferentweeks, and CsA was then withdrawn for five weeks with or
arteriole. In the clinical context, chronic CsA nephrotox-without MMF treatment. Renal function, histologic parame-
icity is difficult to distinguish from chronic allograft ne-ters (tubulointerstitial fibrosis, arteriolopathy, ED-1–positive
cells, renin-positive glomeruli, TUNEL-positive cells) and the phropathy (CAN) [3], but its role in CAN may affect
expression of osteopontin and transforming growth factor nearly 6% of the total renal transplant population [4].
(TGF)-1 mRNA expressions were compared for different Animal model of chronic CsA nephrotoxicity was es-treatment groups.
tablished from the observation that sodium depletion ex-Results. CsA-treated rats showed decreased renal function
acerbates CsA nephrotoxicity [5, 6]. In this model, CsAand increased histologic parameters compared with the vehicle
(VH)-treated rats. The addition of MMF did not improve these treatment in rats on a low salt diet (LSD) induced a
parameters compared with the CsA-treated rats. With CsA histological feature similar to that described in patients
withdrawal, renal function and histologic parameters were sig- on long-term CsA therapy [7]. With this model, it is
nificantly improved compared with the CsA-treated rats, and
known that CsA stimulates the intrarenal renin-angio-MMF treatment after CsA withdrawal further improved the
tensin system [8], transforming growth factor (TGF)-1histologic parameters. At the molecular level, the addition
of MMF did not decrease the expression of osteopontin and production [9], and inflammatory response consisting of
transforming growth factor-1 (TGF-1) mRNAs, which were increased macrophage infiltration and osteopontin ex-
increased in the CsA-treated rat kidney. With CsA withdrawal, pression [10]. In addition, CsA treatment increases the
the expression of both mRNAs was significantly decreased
expression of pro-apoptotic genes [11], and this is medi-
ated by activation of angiotensin II and decreased pro-
duction of nitric oxide [12].Key words: chronic allograft nephropathy, transplantation, nephrotox-
icity, immunosuppression, progressive renal failure. Mycophenolate mofetil (MMF) has been used in solid-
organ transplants as an effective adjunctive immunosup-Received for publication September 12, 2001
pressive agent. MMF selectively suppresses the prolifera-and in revised form February 12, 2002
Accepted for publication February 14, 2002 tion of T and B lymphocytes, inhibits the formation of
antibodies by inhibiting purine nucleotide synthesis, and 2002 by the International Society of Nephrology
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Fig. 1. Experimental design. Two separate
studies were performed. The first study was
designed to evaluate the effect of combined
treatment with cyclosporine A (CsA) and my-
cophenolate mofetil (MMF) on chronic CsA
nephrotoxicity (protocol 1), and the second
study was designed to evaluate the effect of
CsA withdrawal, and subsequent MMF mono-
therapy on chronic CsA nephrotoxicity (pro-
tocol 2).
eliminates guanosine triphosphate of lymphocytes and of CsA-induced nephrotoxicity were observed in an ex-
perimental model of chronic CsA nephrotoxicity.monocytes [13]. In addition to immunosuppression, MMF
has an anti-inflammatory effect as it inhibits the glycosyl-
ation of adhesion molecules [14], osteopontin expression METHODS
[15], and the recruitment of leukocytes to sites to in-
Animals
flammation. Furthermore, MMF inhibits the production
Male Sprague-Dawley rats, weighing 225 to 250 g,of lymphocyte- and macrophage-derived cytokines and
were housed in individual cases in a temperature- andgrowth factors such as platelet-derived growth factor
light-controlled environment in the Catholic University(PDGF), TGF-1, interleukin (IL)-2 and tumor necrosis
Animal Care Facility. The protocol used in these studiesfactor (TNF)- [16]. The anti-inflammatory effect of MMF
was approved by the Catholic University Animal Carehas been observed in experimental models of chronic
Committee. Rats were received a low salt diet (LSD;uremic rats [17, 18] and ischemia-reperfusion injury [19].
0.05% sodium; Teklad Premier, Madison, WI, USA).These findings suggest that MMF treatment may be ef-
fective in reducing chronic CsA nephropathy by decreas- Drugs
ing possible mediators (such as, osteopontin, TGF-1) Cyclosporine A provided by Novartis Research (East
in CsA-induced nephrotoxicity. Hanover, NJ, USA) was diluted in olive oil to a final con-
Recent clinical trials have shown that the addition of centration of 7.5 mg/mL. Mycophenolate mofetil (Cell-
MMF and a reduction in the dose of CsA are effective Cept; Roche Laboratories, Montchair, NJ, USA) was
in preventing the progression of CAN [20–23]. While suspended in sterile water by vigorous agitation, with a
this finding suggests that the CsA dose may be a critical final concentration of 10 mg/mL. The MMF was given
factor in determining graft function in CAN, the effect immediately by gavage once daily, 20 mg/kg in a volume
of MMF on chronic CsA nephropathy has not been ex- of vehicle never exceeding 0.3 mL.
amined. Therefore, our study was designed to evaluate the
Experimental groupeffect of MMF on CsA-induced nephrotoxicity. Chronic
CsA nephrotoxicity was produced using a low-salt diet, Two separate experiments were conducted as outlined
in Figure 1.and the effects of MMF treatment on possible mediators
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Protocol 1. This study was designed to evaluate the described by others [10]. Arteriolopathy of the afferent
arterioles was characterized by expansion of the cell cyto-combined effect of MMF and CsA on chronic CsA neph-
rotoxicity. Animals were divided into three groups. plasm of terminal arteriolar smooth muscle cells by eo-
sinophilic, granular material and semiquantitatively esti-(1) VH10 (vehicle) group: Rats received subcutaneous
injection of olive oil (1 mg/kg) for 10 weeks (N  6). mated by counting the percentage of juxtaglomerular
afferent arterioles with arteriolopathy per total number(2) CsA10 group: Rats received CsA (7.5 mg/kg) for
10 weeks (N  6). of juxtaglomerular arterioles available for examination
with a 20 objective, with a minimum of 60 glomeruli(3) CsA10  MMF group: Rats received CsA for five
weeks and then MMF (20 mg/kg) was administered by per biopsy assessed. Tubulointerstitial fibrosis (TIF) was
semiquantitatively estimated using a color image ana-gavage five weeks later (N  6).
lyzer (Mustek Paragon 800 SP; Macintosh PowerPCProtocol 2. The second study was designed to evaluate
7100, NIH Image v. 1.5) by counting the percentage ofthe effects of withdrawal of CsA and subsequent MMF
injured areas per field. Scores of 0 to 3 were given asmonotherapy in chronic CsA nephrotoxicity.
follows: 0  normal interstitium; 0.5  5%; 1.0  5 to(1) VH5 group: Rats received a daily subcutaneous
15% injury; 1.5  16 to 25% injury; 2.0  26 to 35%injection of olive oil (1 mg/kg) for five weeks (N  6).
injury; 2.5  36 to 45% injury; 3.0  45% injury.(2) CsA5 group: Rats received a daily subcutaneous
injection of CsA (7.5 mg/kg) for five weeks (N  6). Tdt-mediated dUTP-biotin nick end labeling method
(3) CsAW group: Rats received daily subcutaneous (TUNEL assay)
injections of CsA (7.5 mg/kg), and then CsA was with-
Cells undergoing apoptosis were identified using thedrawn for five weeks (N  6).
ApopTag in situ apoptosis detection kit (Oncor, Gaith-(4) CsA5MMF group: Rats received daily subcuta-
ersburg, MD, USA). The sections were dewaxed andneous injection of CsA (7.5 mg/kg), and were then ad-
treated with proteinase K, then incubated with equilibra-ministered MMF (20 mg/kg) after CsA withdrawal for
tion buffer in a humidified chamber for 10 minutes atfive weeks (N  6).
room temperature, followed by incubation with working-
These dosages and routes of administration for CsA strength TdT enzyme solution in a humidified chamber
[24] and MMF [14] were chosen based on previous data. at 37C for two hours. The reaction was terminated by
incubation in working-strength stop/wash buffer for 30
Basic protocol minutes at 37C. After being rinsed with phosphate-buf-
After one week of the LSD, weight-matched rats were fered saline (PBS), the sections were incubated with anti-
randomly assigned to the different treatment groups. digoxigenin peroxidase in a humidified chamber for 30
Daily body weights were recorded. After each treatment minutes at room temperature. Sections were then incu-
period, the systolic blood pressure was measured with a bated with diaminobenzidine and 0.01% H2O2 for five
plethysmography using a tail manometer-tachometer sys- minutes at room temperature. After being rinsed with
tem (BP-2000; Visitech Systems, Apex, NC, USA), and PBS, the sections were counterstained with hematoxy-
24-hour urine samples were collected in metabolic cages lin and examined by light microscopy. The number of
(Nalge Co., Rochester, NY, USA). The following day TUNEL-positive cells was quantitated by sum of 20 fields
animals were anesthetized with ketamine and a blood at 200 magnification [11].
sample and tissue specimens were obtained.
Northern blots for osteopontin and TGF-1 mRNA
Functional studies A 1-kb cRNA probe was generated from the 2B7 cDNA
Urinary and serum creatinine was measured by a Co- clone of rat smooth muscle osteopontin [25]. Sense and
bas autoanalyzer (Roche Diagnostics, Div. Hoffman- antisense cRNA probe were labeled with digoxigenin-
La Roche Inc., Montclair, NJ, USA). Creatinine clear- uridine triphosphate (DIG-UTP) using a T7 RNA poly-
ance (CCr) was calculated using a standard formula. The merase kit (Boehringer Mannheim GmbH, Mannheim,
whole blood CsA concentrations were measured by Germany). Probes were precipitated and incorporation
monoclonal radioimmunoassay (Incstar Co., Stillwater, of DIG was determined by dot blotting. Northern blot-
MN, USA). ting was performed as previously reported [26]. Briefly,
kidney cortex was homogenized and extracted using the
Histology RNAzol reagent (ISO-TEX Diagnostics, USA), and
Tissue samples were fixed in and embedded in wax. 20 	g samples were denatured with glyoxal and dimeth-
Sections 2 to 4 	m were stained with periodic-acid Schiff ylsulfoxide, size fractionated on 1.2% agarose gels and
(PAS) reagent for evaluation of arteriolopathy and with capillary blotted onto positively-charged nylon mem-
Trichrome for evaluation of tubulointerstitial fibrosis. branes (Boehringer). Membranes were hybridized over-
night at 68C or 42C with DIG-labeled cRNA probe inThese histologic findings were evaluated as previously
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Table 1. Body weight, blood pressure and CsA blood levelsa DIG wash and Block Buffer Set solution (Boehringer).
in different groups
Following hybridization, membranes were washed finally
BW SBP CsA levelin 0.1  standard sodium citrate (SSC)/0.1% sodium
Group gram mm Hg ng/mL
dodecyl sulfate (SDS) at 68C or 0.2  SSC/0.1% SDS
VH10 364
21 124
12 N.C.at 42C. Bound probes were detected using sheet anti- CsA10 323
29a 120
10 2291
238
DIG antibody (Fab) conjugated with alkaline phospha- CsA10MMF 336
10a 118
6 2100
199
VH5 319
20 122
11 N.C.tase (Boehringer) and development with CSPD-star
CsA5 295
23b 120
10 2095
125enhanced chemiluminescence (ECL; Boehringer). The CsAW 343
29b,c 127
10 N.C.
CsA5MMF 360
10b,c 118
6 N.C.densitometry analysis was performed using the NIH Im-
age PC program, with three determinations for each Data are mean 
 SEM, N  6 in all groups. Abbreviations are: BW, body
weight; SBP, systolic blood pressure; CsA, cyclosporine; MMF, mycophenolateband that were corrected to 18S. To detect TGF-1 mofetil; VH, vehicle; N.C., not checked.
a P  0.05 vs. VH10 groupmRNA expression, cDNA probes labeled with 32P-dCTP
b P  0.05 vs. VH5 groupby random oligonucleotide priming (Boehringer) were c P  0.05 vs. CsA5 group
used. Data are presented as mean 
 SEM.
Immunohistochemistry for osteopontin,
renin and ED-1 rhea, poor oral intake). Table 1 shows the summary of
body weight, systolic blood pressure and whole bloodSections were dewaxed. Before incubation with pri-
CsA levels in the different groups. Body weight was sig-mary antibody, the sections were blocked with normal
nificantly decreased in the CsA-treated rats comparedrabbit serum diluted 1:10 in 0.3% bovine serum albumin
with the VH-treated rats. No further decrease of body(BSA) for 30 minutes, and incubated for two hours at
weight was observed with addition of MMF. The CsA4C in mouse antiserum against osteopontin (purchased
withdrawal significantly increased body weight com-from the Developmental Studies Hybridoma Bank, Uni-
pared with CsA5 group, but MMF monotherapy afterversity of Iowa, Iowa City, IA, USA) diluted 1:200 in BSA.
CsA withdrawal did not decrease body weight. SystolicThe sections were rinsed in Tris-buffered saline (TBS),
blood pressure measured by tail-cuff pressure was notand incubated for 30 minutes in peroxidase-conjugated
significantly different among study groups, and wholerabbit anti-mouse IgG (Jackson Immuno Research Lab-
blood CsA levels were not significantly different betweenoratories Inc., West Grove, PA, USA). Sections were in-
CsA10 and CsA10MMF groups.cubated with a mixture of 0.05% 3,3-diaminobenzidine
Figure 2 shows renal function in the experimentaland 0.01% H2O2 for five minutes at room temperature, groups. Ten weeks of treatment with CsA significantlywashed with Tris-HCl buffer, counterstained with hema-
reduced the CCr levels (0.20 
 0.03 vs. 0.45 
 0.05 mL/toxylin and examined by light microscopy. The method
min per 100 g) and increased serum creatinine (SCr) lev-for ED-1 or renin immunohistochemistry was similar to
els (1.05 
 0.16 vs. 0.49 
 0.06 mg/dL) compared with
osteopontin immunohistochemistry. The number of ED-1
the VH10 group (P  0.05). The addition of MMF
positive cell was counted at least in 20 fields of cortex (CsA10MMF group) did not improve the SCr (1.01 
per section under 200 magnification, and the number 0.15 mg/dL) or CCr (0.22 
 0.05 mL/min per 100 g) com-of renin-positive glomeruli was counted per 50 glomeruli. pared with the CsA 10 group (P  0.05).
The CsAW group showed a significant decrease in SCrStatistical analysis
(0.95 
 0.13 vs. 0.70 
 0.08 mg/dL; P  0.05) and an
Data reported are mean 
 SEM, and all statistical increase of CCr (0.24 
 0.07 vs. 0.34 
 0.03 mL/min
analyses were calculated with SYSTAT for Macintosh per 100 g; P  0.05) compared with the CsA5 group.
(v. 5.2; SYSTAT Inc., Chicago, IL, USA). Comparisons However, withdrawal of CsA and subsequent MMF
between groups were done by analysis of variance treatment did not improve either parameter compared
(ANOVA) using the Kruskal-Wallis test followed by the with the CsA5 groups (P  0.05).
Tukey or Dunnet test). The level of statistical signifi-
Effect of MMF on arteriolopathy and interstitialcance was P  0.05.
fibrosis in chronic CsA nephrotoxicity
The histology in CsA-treated rats showed typical affer-RESULTS
ent arteriolopathy. The smooth muscle cells the afferent
Effect of MMF on body weight, blood pressure and glomerular arteriole were replaced by a PAS-positive
renal function in chronic CsA nephrotoxicity material, resulting in a typical circumferential appear-
During study period there were no deaths and no ance of the lesion (Fig. 3B). Using a semiquantitative
score, the arteriolopathy was significantly higher in theMMF-related gastrointestinal symptoms (such as diar-
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Fig. 2. Effects of MMF treatment on renal
function in chronic CsA nephrotoxicity. Note
that there is no significant difference in serum
creatinine (SCr) and creatinine clearance (CCr)
between the CsA10 and CsA10MMF groups
(A, B), and the CsAW and CsA5  MMF
(C, D) groups. *P  0.05 vs. VH5 or VH10;
#P  0.05 vs. CsA5.
CsA10 group than the VH10 group (Table 2). The addi- sis of TUNEL-positive cells. In the VH group, TUNEL-
tion of MMF did not decrease the arteriolopathy score positive cells were rarely observed, but their numbers
compared with the CsA10 group. In the CsAW group, increased in the CsA-treated rat kidneys. In the CsA10
there was a significant decrease in the arteriolopathy MMF group, there was no significant decrease in the
score compared with the CsA5 group, and a further number of TUNEL-positive cells compared with the
decrease was observed with the administration of MMF CsA10 group. There was a significant decrease in
after CsA withdrawal. TUNEL-positive cells in the CsAW group (Fig. 6C) com-
The histology in CsA-treated rats showed TIF, in- pared with the CsA5 group, and MMF treatment after
flammatory cell infiltration and tubular atrophy (Fig. 4). CsA withdrawal further reduced the number of TUNEL-
When the extent of changes in TIF was graded using a positive cells (Fig. 6D).
0 to 4 semiquantitative score, the addition of MMF
did not decrease the TIF score compared with the CsA10 Effect of MMF on intrarenal renin expression in
group (2.1 
 0.5 vs. 2.3 
 0.6; P  0.05). In the CsAW chronic CsA nephrotoxicity
group, there was a significant decrease in the TIF score
Figure 7 shows the intrarenal expression of renin incompared with the CsA5 group (1.5 
 0.4 vs. 2.0 
 0.6;
different experimental groups. Intrarenal expression ofP  0.05), and a further decrease was observed with the
renin was minimal in the VH group, but this immunore-administration of MMF after CsA withdrawal (vs. 1.0 

activity and the number of renin-positive glomeruli in-0.3; P  0.05; Fig. 5).
creased in the kidneys with CsA treatment. Quantitative
Effect of MMF on apoptotic cell death in analysis of renin-positive glomeruli in rat kidney (Ta-
chronic CsA nephrotoxicity ble 2) revealed significant increase in the number of
renin-positive glomeruli in the CsA10 group comparedFigure 6 shows TUNEL-staining in different experi-
mental groups and Table 2 shows the quantitative analy- with the VH group. The addition of MMF (CsA10 
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Fig. 3. Effect of MMF treatment on arteriolopathy in chronic CsA
nephrotoxicity. (A) VH5 group showing a normal glomerulus. (B) CsA5
group with the glomerulus showing expansion of the cell cytoplasm of
terminal arteriolar smooth muscle cells by eosinophilic, granular mate-
rial (arrow). (C ) CsAW group with the glomerulus showing regression
of arteriolar hyalinization. (D) CsA5MMF group with the glomerulus Fig. 4. Effect of the combined treatment with CsA and MMF on inter-
showing almost absence of arteriolar hyalinization. (PAS stain, magni- stitial fibrosis in established chronic CsA nephrotoxicity. CsA treatment
fication 400). for 10 weeks produced interstitial fibrosis, inflammatory cells infiltra-
tion, and tubular atrophy. Note there is no significant improvement of
tubulointerstitial fibrosis (TIF) with the addition of MMF in chronic
CsA nephrotoxicity (Trichrome stain, magnification 100; *P  0.05Table 2. Arteriolopathy, number of TUNEL-positive cells
vs. VH10).and renin-positive glomeruli in different groups
Arteriolopathy TUNEL-positive Renin-positive
Group % cells glomeruli group (3 
 2), but their number increased with CsA
VH10 5
2 2
2 11
3 treatment for 10 weeks (22
 5; P 0.05). Simultaneous
CsA10 59
13a 54
15a 25
2a
administration of MMF and CsA slightly decreasedCsA10MMF 51
12a 52
17a 22
2a
VH5 4
3 3
2 10
4 ED-1–positive cells, though this was not statistically sig-
CsA5 48
19b 45
14b 21
3b nificant (18
 6; P 0.05). In the CsA withdrawal group,
CsAW 32
8b,c 28
15b,c 17
4b,c
ED-1–positive cells were decreased significantly as com-CsA5MMF 20
6b,d 18
7b,d 13
3b,c,d
pared with the CsA5 group (17 
 3 vs. 13 
 4, P Data are mean
 SEM, N 6 in all groups. Arteriolopathy was semiquantita-
tively measured by counting the percentage of juxtaglomerular afferent arterioles 0.05), and further decrease of ED-1-positive cells was
with arteriolopathy per total number of juxtaglomerular arterioles available for observed with MMF treatment in the CsA-withdrawnexamination with 20 objective, with a minimum of 60 glomeruli per biopsy.
The number of apoptosis positive cells per 20 fields was determined using the state (vs. 7 
 2, P  0.05; Fig. 9).
TUNEL assay at a 200 magnification. The number of renin-positive glomeruli
are taken from a universe of 50 glomerui examined. Effect of MMF on osteopontin expression ina P  0.05 vs. VH10
b P  0.05 vs. VH5 chronic CsA nephrotoxicity
c P  0.05 vs. CsA5
d P  0.05 vs. CsAW Northern blot and immunohistochemical analyses
were used to assess osteopontin expression. In the CsA10
group, there was 3.7-fold increase in osteopontin mRNA
MMF group) did not reduce the number of renin-positive expression compared with the VH10 group. The addition
glomeruli; however, withdrawal of CsA significantly de- of MMF did not decrease osteopontin expression (Fig.
creased the number of renin-positive glomeruli (Fig. 7C) 10). The CsAW group showed a decrease in osteopontin
compared with the CsA5 group, and a further decrease mRNA expression compared with the CsA5 group
was observed with MMF treatment (Fig. 7D). (2.5- vs. 1.8-fold, respectively, compared with the VH
group; P  0.05), and the CsA5  MMF group showed
Effect of MMF on macrophage infiltration in a further decrease compared with the CsAW group (1.3-
chronic CsA nephrotoxicity fold relative the VH group; Fig. 11). Minimal immunore-
Figure 8 shows the ED-1-positive cells in CsA-treated activity for osteopontin was evident in the VH-treated
rat kidney, but the extent and immunoreactivity of osteo-rat kidneys. ED-1–positive cells were minimal in the VH
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Fig. 6. Effect of MMF on apoptotic cell death detected by TUNEL-
staining in chronic CsA nephrotoxicity. (A) VH5 group. Note the lack
of TUNEL-positive cells. (B) CsA5 group. Note the significant increase
in TUNEL-positive cells (arrows) in chronic CsA nephrotoxicity. (C )
CsAW group. Note the decrease in TUNEL-positive cells. (D) CsA5 
MMF group. Note the further decrease of TUNEL-positive cells with
MMF treatment after CsA withdrawal (magnification, 200).
Fig. 5. Effect of CsA withdrawal or MMF administration on tubuloin-
terstitial fibrosis (TIF) in established chronic CsA nephrotoxicity. Treat-
ment with CsA for five weeks resulted in a pathology typical of chronic
CsA nephrotoxicity. With CsA withdrawal, interstitial fibrosis decreased
compared with the CsA5 group, and a further decrease in interstitial fi-
brosis was observed with MMF treatment after CsA withdrawal. (Magni-
fication, 100; *P  0.05 vs. VH5; #P  0.05 vs. CsA5; %P  0.05 vs.
CsAW).
Fig. 7. Effect of MMF on intrarenal renin expression in chronic CsA
pontin protein increased with CsA treatment, and was nephrotoxicity. (A) The VH5 group shows a minimal immunoreactivity
of renin. (B) The CsA5 group has a significantly increased immunoreac-observed in injured tubules and interstitial areas. Simul-
tivity and extent of renin-positive glomeruli (arrows). (C) The CsAWtaneous administration of CsA and MMF did not cause group has reduced renin-positive glomeruli (arrows). (D) The CsA5 
a decrease in immunoreactivity compared with the CsA5 MMF group has a further decrease of renin-positive glomeruli (arrows)
with MMF treatment after CsA withdrawal (magnification, 200).group, but such a decrease was evident in the CsAW
and CsA5  MMF groups.
Effect of MMF on TGF-1 mRNA expression in with the VH10 group, but the addition of MMF did not
chronic CsA nephrotoxicity decrease this expression. With CsA withdrawal, TGF-1
mRNA expression was significantly decreased comparedCyclosporine A treatment for 10 weeks caused a 3.9-
fold increase in TGF-1 mRNA expression compared with the CsA5 group (2.9- vs. 2.3-fold, respectively; P 
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Fig. 8. Effect of MMF on macrophage infiltration in chronic CsA neph-
rotoxicity. The CsA10 group showed a significant increase of ED-1–
positive cells compared with the VH group. Note that there is no
significant decrease in ED-1-positive cells with the addition of MMF
in established chronic CsA nephrotoxicity (magnification, 200; *P 
0.05 vs. VH10).
0.05), and a further decrease was observed with MMF
treatment (1.8-fold; P  0.05; Fig. 12).
Fig. 9. Effect of CsA withdrawal and MMF monotherapy on macro-
phage infiltration in chronic CsA nephrotoxicity. (A) Immunohisto-
DISCUSSION chemical analysis of ED-1. Note the increased immunoreactivity in the
CsA-treated rat kidney. (B) Quantitative analysis of ED-1–positive cellsThe results of our study clearly show that concurrent
in the experimental groups. Note that ED-1–positive cells are increased
administration of MMF and CsA is negligibly effective in the CsA5 group, and decreased in the CsAW and CsA5MMF
groups (magnification, 200; *P  0.05 vs. VH5; #P  0.05 vs. CsA5;in preventing the development chronic CsA nephrotox-
%P  0.05 vs. CsAW).icity, but MMF monotherapy as well as withdrawal of
CsA is effective in inhibiting its progression. The results
of our study clarify the roles of MMF or CsA in the pro-
gression of chronic CsA nephrotoxicity, and provide a et al, Am Soc Transplant Physicians Abstract Book
rationale for MMF use in chronic CsA nephrotoxicity. 16:134 (197A), 1997]. The addition MMF to prednisone-
It is well known that MMF inhibits the proliferation CsA therapy without a reduction of in the CsA dose
of resident renal cells [27, 28] and collagen deposition conferred no significant benefit on patients with CAN.
[29]. Furthermore, MMF inhibits the production of lym- These findings suggest that the anti-inflammatory action
phocyte- and macrophage-derived TGF-1, TNF-, and of MMF is not strong enough to overcome CsA-induced
IFN- in specific experimental models [16, 30]. There- nephrotoxicity when the kidney is continuously exposed
fore, considering the variety of potentially beneficial ac- to CsA. Therefore, the dose of CsA may be one of the
tions attributed to MMF, we expected MMF to have a factors in determining graft function in CAN.
protective effect on CsA-induced nephrotoxicity. How- The effect of CsA withdrawal on the progression of
ever, our study demonstrated no beneficial effects from chronic CsA nephrotoxicity depends upon the accumu-
the administration of MMF in inhibiting chronic CsA lated CsA dose and the timing of CsA withdrawal [31].
nephrotoxicity. Similar results were reported from a hu- The results of our study revealed that CsA withdrawal
man study [abstracts; Schurter et al, Am Soc Transplant significantly improved not only renal function, but also
histologic parameters (apoptotic cell death, inflamma-Physicians Abstract Book 16:133 (196A), 1997; and Smith
Yang et al: MMF and chronic CsA nephrotoxicity28
Fig. 10. Effect of combined treatment with
CsA and MMF on osteopontin mRNA and
protein expression. (A) Northern blot analysis
for osteopontin mRNA. (B) Relative expres-
sion of osteopontin mRNA. (C ) Immunohis-
tochemical analysis of osteopontin. Note the
significant increase of osteopontin mRNA and
protein expression the CsA10 group. How-
ever, there was no significant difference in
osteopontin expression between the CsA10
and CsA10  MMF groups (magnification,
200; *P  0.05 vs. VH10).
Fig. 11. Effect of CsA withdrawal or MMF monotherapy on osteopontin mRNA and protein expression in chronic CsA nephrotoxicity. (A)
Northern blot analysis of osteopontin mRNA. (B) Relative expression of osteopontin mRNA. (C ) Immunohistochemical analysis of osteopontin.
Note the significant increase in osteopontin mRNA or protein in CsA-treated rat kidney. With CsA withdrawal, osteopontin mRNA expression
decreased significantly and a further decrease was observed with MMF treatment after CsA withdrawal (magnification, 200; *P  0.05 vs. VH5;
#P  0.05 vs. CsA5; %P  0.05 vs. CsAW).
Yang et al: MMF and chronic CsA nephrotoxicity 29
Fig. 12. Effect of MMF treatment on TGF-1
mRNA expression in chronic CsA nephrotox-
icity. (A) The combined effect of CsA and
MMF on TGF-1 mRNA expression in estab-
lished chronic CsA nephrotoxicity. Note the
significant increase of TGF-1 mRNA expres-
sion in CsA-treated rat kidney, but no signifi-
cant decrease of TGF-1 mRNA expression
with addition of MMF. (B) Effect of CsA with-
drawal or MMF monotherapy on TGF-1
mRNA expression in chronic CsA nephrotox-
icity. Note the significant decrease of TGF-1
mRNA expression with CsA withdrawal as
compared with the CsA group, and further
decrease of TGF-1 mRNA expression with
MMF treatment in the CsA-withdrawal state
(*P  0.05 vs. VH5 or VH10; #P  0.05 vs.
CsA5; %P  0.05 vs. CsAW).
tory cell infiltration, arteriolopathy and TIF) in rat kid- the RAS has not been fully understood, but two recent
studies revealed that MMF treatment decreased angio-neys. At the molecular level, histologic improvement was
accompanied by decreased expression of renin-positive tensin II-positive cells among infiltrating mononuclear
cells in an animal model of salt-sensitive hypertensionglomeruli, osteopontin and TGF-1 mRNAs. This find-
ing is consistent with human studies that described the [35, 36]. Our current study evaluated intrarenal renin ex-
pression using immunohistochemistry, and quantitativeeffects of reduction or withdrawal of CsA on CAN (ab-
stracts; Wei et al, J Am Soc Nephrol 10:92A, 1999; Song analysis revealed that MMF treatment after CsA with-
drawal as well as CsA withdrawal alone significantlyet al, Transplantation 67:S236, 1999). Based on above
findings, we suggest that the mechanism underlying the decreased the number of renin-positive glomeruli in
chronic CsA nephrotoxicity. On the basis of our studybenefits of CsA withdrawal is associated with a reduction
of RAS activity and a decrease in the profibrogenic cyto- and a previous report, we propose that that renoprotec-
tive effect of MMF on chronic CsA nephrotoxicity maykine (TGF-1) or proinflammatory cytokines (osteopon-
tin), which play an important role in the pathogenesis be related, in part, to the decreased activity of the RAS.
Reports have shown that MMF is effective in reducingof chronic CsA nephrotoxicity [9, 10].
The result of this study indicates that the MMF treat- CAN when the CsA dose is reduced to 50% [20], or low
trough levels (40 to 60 ng/mL) [21], or even after CsAment in the CsA-withdrawal state decreases chronic CsA
nephrotoxicity. In evaluating possible mechanisms re- withdrawal [23]. These findings suggest that CsA-induced
nephrotoxicity potentially influences CAN, and providessponsible for the protection offered by MMF, we first
suggest that the reduction of tubulointerstitial damage a rationale for the reduction or withdrawal of CsA and
the use of non-nephrotoxic immunosuppressants suchby MMF may be a consequence of the suppression of
the local inflammatory reaction that is fueled by the as MMF and rapamycin in current immunosuppression
regimens [37, 38]. This strategy involves the reductioninfiltration of inflammatory cells [13, 18, 32]. In the pres-
ent study, increased ED-1–positive cells and up-regu- of CsA-induced nephrotoxicity and the maximization of
immunosuppression with non-nephrotoxic drugs. In ourlated expression of osteopontin and TGF-1 mRNAs in
CsA-treated rat kidneys were significantly decreased with study, the effects of MMF on rats treated with reduced
CsA dose were not evaluated, but we postulate that a re-MMF treatment after CsA withdrawal. This finding sug-
gests that MMF itself may attenuate tubulointerstitial duction in the CsA dose may have beneficial effects on
renal function and histology in CsA-induced nephrotox-inflammation and fibrosis by inhibiting pro-inflammatory
and pro-fibrogenic cytokines [33]. icity. Furthermore, enhanced immunosuppression with
MMF may be beneficial in clinical practice. Further studyIt also is possible that MMF treatment inhibits the
renin-angiotensin system (RAS) in CsA-treated rat kid- is required to evaluate the appropriate doses of CsA and
MMF to achieve optimal immunosuppression while avoid-ney. Activation of the RAS is associated with the patho-
genesis of chronic CsA nephrotoxicity [5], and blocking ing the deterioration in graft function caused by CsA.
In summary, our present study clarifies the roles ofthis system with enalapril or losartan prevents chronic CsA
nephrotoxicity [34]. Until now, the influence of MMF on CsA and MMF in the progression of chronic CsA neph-
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